A Homotypic Membrane-Camouflaged Biomimetic Nanoplatform with Gold Nanocrystals for Synergistic Photothermal/Starvation/Immunotherapy
Source abstract
Abstract
Although photothermal therapy (PTT) has great potential for tumor inhibition, this single mode of action frequently encounters recurrence and metastasis, highlighting the urgent need for developing combination therapy. Inspired by established evidence that PTT could induce efficient immunogenic cell death (ICD), we here developed a versatile biomimetic nanoplatform (denoted as AuDRM) for the synergism of photothermal/starvation/immunotherapy against cancer. Specifically, dendritic mesoporous silica nanoparticles (NPs) were successfully constructed followed by the in situ synthesis of Au NPs in the mesopores. Afterward, a hybrid membrane was coated to facilitate the loading of R837. Upon efficient accumulation in the tumor tissue by homotypic targeting, the pH-sensitive membrane could be jettisoned to ensure the exposure of Au NPs for starvation therapy and the effective release of the immunostimulator R837 for enhancement of immunotherapy. Except for the PTT-mediated tumor ablation, the induction of ICD coupled with the release of tumor antigens could work synergistically with the immunostimulator R837 for inhibiting the primary tumor as well as the metastasis and induce a long-term immune memory effect for tumor inhibition via a vaccine-like function. Thus, this study paves the way for high-performance tumor ablation by the synergism of photothermal/starvation/immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beijing 100083, China
Beijing Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing 100083, China
Funding
the International S&T Cooperation Program of China
References (53)
Show source-provided references
1. 10.1039/C7NR05382G10.1039/C7NR05382G ↗
2. 10.1038/nrc216710.1038/nrc2167 ↗
3. 10.1016/S0140-6736(16)30958-810.1016/S0140-6736(16)30958-8 ↗
4. 10.1002/adma.20160211110.1002/adma.201602111 ↗
5. 10.1039/D0TB00676A10.1039/D0TB00676A ↗
6. 10.1007/s12274-020-2722-z10.1007/s12274-020-2722-z ↗
7. 10.1056/NEJMoa140844010.1056/NEJMoa1408440 ↗
8. 10.1002/adhm.20160105810.1002/adhm.201601058 ↗
9. 10.1002/smll.20190767710.1002/smll.201907677 ↗
10. 10.1039/C4NR00708E10.1039/C4NR00708E ↗
11. 10.1021/jacs.6b1138210.1021/jacs.6b11382 ↗
12. 10.1038/ncomms1296710.1038/ncomms12967 ↗
13. 10.1038/s41467-021-21047-010.1038/s41467-021-21047-0 ↗
14. 10.1021/acsnano.7b0687010.1021/acsnano.7b06870 ↗
15. 10.1002/adfm.20170037110.1002/adfm.201700371 ↗
16. 10.1002/anie.20181127310.1002/anie.201811273 ↗
17. 10.1002/adma.20170126610.1002/adma.201701266 ↗
18. 10.1038/nmat470710.1038/nmat4707 ↗
19. 10.1002/adma.20200345810.1002/adma.202003458 ↗
20. 10.1002/adma.20190509110.1002/adma.201905091 ↗
21. 10.1039/D0SC03173A10.1039/D0SC03173A ↗
22. 10.1021/acsami.9b1396610.1021/acsami.9b13966 ↗
23. 10.1002/adma.20140299610.1002/adma.201402996 ↗
24. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
25. 10.1056/NEJMoa180961510.1056/NEJMoa1809615 ↗
26. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
27. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
28. 10.1021/acs.accounts.9b0014810.1021/acs.accounts.9b00148 ↗
29. 10.1038/nrc323910.1038/nrc3239 ↗
30. O’Donnell J. S. · Nat. Rev. Clin. Oncol. · 2018 · 16 · 15110.1038/s41571-018-0142-8 ↗
31. 10.1038/ncomms1319310.1038/ncomms13193 ↗
32. 10.1039/C8CS00473K10.1039/C8CS00473K ↗
33. 10.1016/j.chempr.2019.05.01310.1016/j.chempr.2019.05.013 ↗
34. 10.1002/anie.20180488210.1002/anie.201804882 ↗
35. 10.1038/s41568-019-0186-910.1038/s41568-019-0186-9 ↗
36. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
37. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
38. 10.1002/adma.20200806110.1002/adma.202008061 ↗
39. 10.1002/adfm.20200439710.1002/adfm.202004397 ↗
40. 10.1039/C8CS00896E10.1039/C8CS00896E ↗
41. 10.1002/adfm.20170413510.1002/adfm.201704135 ↗
42. 10.1002/adfm.20160598510.1002/adfm.201605985 ↗
43. 10.1016/j.smaim.2020.05.00210.1016/j.smaim.2020.05.002 ↗
44. 10.1038/nmat125110.1038/nmat1251 ↗
45. 10.1002/advs.20180173310.1002/advs.201801733 ↗
46. 10.1021/acsnano.8b0378810.1021/acsnano.8b03788 ↗
47. 10.1021/acs.nanolett.9b0381710.1021/acs.nanolett.9b03817 ↗
48. 10.1016/j.biomaterials.2019.11963610.1016/j.biomaterials.2019.119636 ↗
49. 10.1002/adhm.20150027310.1002/adhm.201500273 ↗
50. 10.1021/acs.accounts.9b0056910.1021/acs.accounts.9b00569 ↗
51. 10.1021/acsnano.0c0539210.1021/acsnano.0c05392 ↗
52. 10.1021/acs.chemmater.5b0396310.1021/acs.chemmater.5b03963 ↗
53. 10.1039/D0BM01168A10.1039/D0BM01168A ↗